These data are in line with the dismal prognostic role of CD133 expression in cancer tissues [125], and support the future exploitation of CD133+ CD326- ECVs as diagnostic and prognostic biomarkers to be evaluated in defined cancer types and treatment settings. This evidence concerns the gene PROM1 and cancer.